Dr. Argiles Discusses the Role of Immunotherapy in CRC

Guillem Argiles, MD, staff member, Gastrointestinal Malignancies Division, Vall d’Hebron University Hospital, discusses the role of immunotherapy in colorectal cancer (CRC).

There is an important role for immunotherapy in the hyper-mutant population of patients with CRC, says Argiles.

As of now, pembrolizumab (Keytruda) is approved in the United States for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high or mismatch repair deficient solid tumors.